Qualcomm Announces Quarterly Cash Dividend
Get Alerts QCOM Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: -14.2%
Join SI Premium – FREE
About Qualcomm
Qualcomm is a global computing leader at the center of the AI era, enabling intelligence to scale from the most personal devices to large‑scale infrastructure. Building on more than four decades of innovation, we develop platforms and solutions that bring together advanced AI, high‑performance, low-power computing and industry‑leading connectivity—powering products and services used around the world. At Qualcomm, we are engineering human progress.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patents are licensed by Qualcomm Incorporated. Qualcomm, Snapdragon, Qualcomm Dragonwing and Qualcomm Dragonfly are trademarks or registered trademarks of Qualcomm Incorporated. For more information, visit www.qualcomm.com.
Qualcomm Contact:
Brett Simpson, Investor Relations
Phone: 1-858-658-4813
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/qualcomm-announces-quarterly-cash-dividend-302914728.html
SOURCE Qualcomm Incorporated
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BCE announces partnership with La Caisse, which will acquire 49.9% stake in Bell wireless tower infrastructure company
- Wynn Showcases Chinese Wines on a Global Stage as "Strategic Wine Partner" for the Tatler Best Asia Pacific 2026
- Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share